We have an update on the case of a University of Utah lab that retracted two Cell Metabolism papers last month after a fired lab technician disposed of two lab notebooks without permission. The team has now corrected two other papers, one in Blood and the other in the Journal of Clinical Investigation.
Here’s the notice from Blood:
Correction to De Domenico et al. 110 (10): 3780
De Domenico I, Vaughn MB, Yoon D, Kushner JP, Ward DM, Kaplan J. Zebrafish as a model for defining the functional impact of mammalian ferroportin mutations. Blood. 2007;110(10):3780–3783.
On page 3781 of the 15 November 2007 issue, there is an error in Figure 1. The panel depicting Fpn-GFP N144H in Figure 1B was inadvertently duplicated from another panel in the original published figure. The authors have replaced the panel with the correct image. The findings of the paper have not been affected by the error. The authors apologize to the editors and readers for this mistake. The corrected figure is shown.
Expression of mutant Fpn in zebrafish affects hemoglobinization of erythrocytes. Zebrafish embryos were injected with wild-type or mutant Fpn-GFP. At 48 hpf, the embryos were homogenized (A), and Fpn-GFP levels were assayed by Western blot analysis or (B) stained with o-dianisidine to detect hemoglobinized cells (brown color denoted by the arrow). The figures are representative of 6 different experiments in which 100 embryos were injected with each construct. The survival rate (n = 600) was 69.6% for embryos injected with wild-type constructs, 50.8% for embryos injected with H32R constructs, 64.7% for embryos injected with N144H constructs, and 48.2% for embryos injected with N174I constructs. (C) Embryos were injected with wild-type or H32R constructs with or without coinjection of iron-dextran. The survival rate was 70% for wild-type embryos injected with or without iron-dextran, 50% for wild-type embryos injected with H32R without iron-dextran, and 62% for wild-type embryos injected with iron-dextran.
And here’s the one from the JCI:
Hepcidin mediates transcriptional changes that modulate acute cytokine-induced inflammatory responses in mice
Ivana De Domenico, Tian Y. Zhang, Curry L. Koening, Ryan W. Branch, Nyall London, Eric Lo, Raymond A. Daynes, James P. Kushner, Dean Li, Diane M. Ward and Jerry Kaplan
Published June 1, 2012
Original citation: J. Clin. Invest. 2010;120(7): 2395–2405. doi:10.1172/JCI42011.
Citation for this corrigendum: J. Clin. Invest. 2012;122(6):2326. doi:10.1172/JCI63977.
The anti-Fpn and anti-Jak2 rows in Figure 2A were reprinted from I. De Domenico et al. (ref. 10) without attribution. They represent the same rows as were present in Figure 3B of that manuscript.
The authors regret the error.
Of note: Reference 10 of the JCI paper is a PNAS paper that the team has already corrected, as we reported last month. According to the PNAS correction notice, Figure 3b was
replaced due to errors in preparing the figure for publication.
So it’s unclear which version the figures in the JCI paper came from. It’s also unclear whether the same dismissed technician involved in the Cell Metabolism retractions was involved in these figure errors.
We’ve been trying since Monday to contact senior author Jerry Kaplan for comment on those issues, as well as to find out whether there are any more corrections or retractions planned, and will update with anything we find out.
Hat tip: Commenter Anonymous